ACADIA Pharmaceuticals (ACAD) Stock Forecast & Price Target $17.03 +0.26 (+1.55%) (As of 11/18/2024 ET) Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ACADIA Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024) How MarketBeat Calculates Price Target and Consensus Rating MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Consensus Rating Moderate BuyBased on 17 Analyst RatingsSell0Hold6Buy11 Based on 17 Wall Street analysts who have issued ratings for ACADIA Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 17 analysts, 6 have given a hold rating, and 11 have given a buy rating for ACAD. Consensus Price Target $25.5650.10% Upside According to the 17 analysts' twelve-month price targets for ACADIA Pharmaceuticals, the average price target is $25.56. The highest price target for ACAD is $42.00, while the lowest price target for ACAD is $19.00. The average price target represents a forecasted upside of 50.10% from the current price of $17.03. Get the Latest News and Ratings for ACAD and Related Stocks Enter your email address to receive the latest news and analysts' ratings for ACADIA Pharmaceuticals and its competitors. Enter your email to sign up for newsletter Sign Up ACAD Analyst Ratings Over TimeTypeCurrent Forecast11/19/23 to 11/18/241 Month Ago10/20/23 to 10/19/243 Months Ago8/21/23 to 8/20/241 Year Ago11/19/22 to 11/19/23Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy11 Buy rating(s)11 Buy rating(s)11 Buy rating(s)9 Buy rating(s)Hold6 Hold rating(s)6 Hold rating(s)5 Hold rating(s)3 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$25.56$25.56$25.56$35.67Forecasted Upside50.10% Upside67.08% Upside64.18% Upside56.16% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyModerate Buy I was wrong. Dead wrong. (Ad)One small investment into these three companies at IPO and you’ve outperformed almost any other investment you could make. Unfortunately, you can’t go back in time and invest in what became the three most dominant companies in the tech world.Click here to watch. ACAD Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History ACAD Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table ACADIA Pharmaceuticals Stock vs. The CompetitionTypeACADIA PharmaceuticalsMedical CompaniesS&P 500Consensus Rating Score 2.65 2.80 2.50Consensus RatingModerate BuyModerate BuyModerate BuyPredicted Upside53.07% Upside28,933.14% Upside9.44% UpsideNews Sentiment RatingNeutral NewsSee Recent ACAD NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails11/7/2024HC Wainwright2 of 5 stars Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00+70.99%11/7/2024Needham & Company LLC3 of 5 stars Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00+77.33%10/10/2024Raymond James4 of 5 starsD. BrillSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform8/8/2024CitigroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetBuy ➝ Buy$30.00 ➝ $23.00+48.67%8/8/2024UBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetBuy ➝ Buy$25.00 ➝ $23.00+49.45%8/7/2024Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetOverweight ➝ Overweight$37.00 ➝ $28.00+82.17% Get the Latest News and Ratings for ACAD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 8/7/2024Royal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetOutperform ➝ Outperform$29.00 ➝ $26.00+67.31%8/7/2024Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy rating DowngradeOverweight ➝ Equal Weight$28.00 ➝ $20.00+6.10%6/27/2024BMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingE. SeigermanSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$31.00+100.00%5/10/2024Bank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetNeutral ➝ Neutral$26.00 ➝ $22.00+44.64%5/9/2024Stifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetHold ➝ Hold$26.00 ➝ $21.00+30.84%5/9/2024Robert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetOutperform ➝ Outperform$31.00 ➝ $28.00+63.46%5/9/2024MizuhoSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetNeutral ➝ Neutral$25.00 ➝ $21.00+22.59%5/6/2024OppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingMarket Perform ➝ Market Perform$19.00 ➝ $19.00+11.44%3/25/2024JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetOverweight ➝ Overweight$29.00 ➝ $25.00+40.53%2/7/2024JMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingMarket Outperform ➝ Market Outperform$42.00+66.67%12/12/2023Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageBuy ➝ Buy$25.00+18.54%8/3/2023Canaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetBuy ➝ Buy$39.00 ➝ $38.00+36.01%4/28/2023Credit Suisse GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost Target$93.00 ➝ $95.00+363.41%3/14/2023GuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost Target$22.00 ➝ $25.00+28.80%3/14/2023Jefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost Target$10.00 ➝ $15.00-22.72%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 07:35 PM ET. ACAD Forecast - Frequently Asked Questions What is ACADIA Pharmaceuticals' forecast for 2025? According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for ACADIA Pharmaceuticals is $25.56, with a high forecast of $42.00 and a low forecast of $19.00. Should I buy or sell ACADIA Pharmaceuticals stock right now? 17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 6 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ACAD shares. Does ACADIA Pharmaceuticals's stock price have much upside? According to analysts, ACADIA Pharmaceuticals's stock has a predicted upside of 50.10% based on their 12-month stock forecasts. What analysts cover ACADIA Pharmaceuticals? ACADIA Pharmaceuticals has been rated by research analysts at HC Wainwright, Needham & Company LLC, and Raymond James in the past 90 days. Do Wall Street analysts like ACADIA Pharmaceuticals more than its competitors? Analysts like ACADIA Pharmaceuticals less than other "medical" companies. The consensus rating score for ACADIA Pharmaceuticals is 2.65 while the average consensus rating score for "medical" companies is 2.80. Learn more on how ACAD compares to other companies. Stock Forecasts and Research Tools Related Companies ARWR Stock Forecast IONS Stock Forecast JAZZ Stock Forecast SRPT Stock Forecast CTLT Stock Forecast RVMD Stock Forecast QGEN Stock Forecast ITCI Stock Forecast ROIV Stock Forecast ASND Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter I was wrong. Dead wrong. (Ad)Deep inside Silicon Valley the alarm bells are ringing… Jeff Bezos just sold $3 billion in Amazon stock. Warren Buffet just sold another 100 million Apple shares. Yet while the insiders are dumping shares, millions of unsuspecting investors are dumping more and more money in… blind to the carnage that’s just around the corner.Click here to watch. This page (NASDAQ:ACAD) was last updated on 11/18/2024 by MarketBeat.com Staff From Our PartnersTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this ...Crypto 101 Media | SponsoredWhy Buffett, Bezos & Congress Are Rushing Into This SectorWhy are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredTech funds are hemorrhaging cash: Sell this stock nowSomething very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s EPIC Stock Market RallyPutting HUGE gain chances in the hands of hardworking, patriotic Americans like YOU. In fact, according to ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
